Genmab Price to Book Ratio 2019-2021 | GMAB

Historical price to book ratio values for Genmab (GMAB) over the last 10 years. The current price to book ratio for Genmab as of December 07, 2021 is 7.54.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Genmab Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-12-06 36.92 7.18
2021-09-30 43.70 $5.14 8.50
2021-06-30 40.83 $5.00 8.16
2021-03-31 32.83 0.00
2020-12-31 40.66 $4.47 9.10
2020-09-30 36.61 0.00
2020-06-30 33.89 0.00
2020-03-31 21.19 0.00
2019-12-31 22.33 $3.24 6.90
2019-09-30 20.26 $2.87 7.06
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $25.453B $1.549B
Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $126.808B 8.01
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $6.887B 0.00
Arcus Biosciences (RCUS) United States $3.210B 0.00
Emergent Biosolutions (EBS) United States $2.270B 8.16
Myovant Sciences (MYOV) United Kingdom $1.508B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.469B 0.00
Zymeworks (ZYME) Canada $0.850B 0.00
SQZ Biotechnologies (SQZ) United States $0.326B 0.00
Ambrx Biopharma (AMAM) United States $0.322B 0.00
Enzo Biochem (ENZ) United States $0.170B 16.71